test header

Oncology

ELCC

Copenhagen

Poster

MountainTAP-29: a randomized phase 2/3 study of first-line navlimetostat (BMS-986504) + pembrolizumab + chemotherapy in patients with metastatic NSCLC with homozygous MTAP deletion

Solange Peters, Konstantinos Leventakos, Martin Reck, Hibiki Ugadawa, Natalie Vokes, Yi-Long Wu, Jennifer (Jiping) Zhang, Srivani Konduri, Federico Campigotto, Pasi A. Jänne

Poster

Clinical, genomic, and tumor microenvironment characterization of MTAP-deletion in advanced/metastatic non-small cell lung cancer

Martin Reck, Micaela Tatman, Chunan Liu, Yu-Han Hung, Solange Peters, Martin Schuler, Tapsi Kumar, Rachel Webster, Wen-Chi Chou, Jaclyn Neely, Tyler Simpson, Bogdan-Alexandru Luca, Ruslan Novosiadly, Aparna Chhibber, Ming Lei

Poster

Interim Data On First-line (1L) Nivolumab (N) + Ipilimumab (I) With 2 Cycles of Platinum-based Chemotherapy (C) In Patients (pts) With Metastatic Non-small Cell Lung Cancer (mNSCLC) from the German Non-interventional Study (NIS) FINN

Christian Schumann, Dirk Behringer, Jonas Kuon, Parvis Sadjadian, Wolfgang Blau, André Hassler, Stefan Wilop, Manfred Welslau, Carsten Ziske, Dimitri Flieger, Stephan Kreher, Matthias Groschek, Gerdt Hübner, André Althoff, Ina Dittrich, Migle Link, Tobias Bluhmki, Daniela Waldenberger, Sylvia Gütz, Eyck von der Heyde

Poster

Interim Data On Neoadjuvant Nivolumab Plus Platinum-based Chemotherapy (Neoadj NIVO+CT) in Patients (Pts) with Non-metastatic Resectable NSCLC From the Non-interventional Study (NIS) NENI

Christian Meyer zum Büschenfelde, Marcel Reiser, Miriam Möller, Jörg Kluge, Martin Faehling, Ernst Rodermann, Matthias Müller, Stefan Hammerschmidt, Jonas Kuon, André Bethge, Wolfgang Blau, Ludger Hillejan, Philipp Meyn, Eyck von der Heyde, Frank Griesinger, Tobias Bluhmki, Katrin Dauber, Daniela Waldenberger, Martin Eichhorn

Poster

Tumor and Nodal Pathological Response After Neoadjuvant Nivolumab Plus Chemotherapy in a Cohort Of 622 Patients with Resectable NSCLC: Results From a French Multicenter Study

Francesca Lucibello, Marie Wislez, Romain Vergé, Pierre Demontrond, Quentin Thomas, Patrick Merle, Nicolas Verger, Anne Madroszyk, Benoit Roch, Ayoube Zouak, Benoit Godbert, Emmanuel Grolleau, Charles Naltet, Ludovic Doucet, Florian Guisier, Alexis Prudent, Florence Brellier, Nadia Hegarat, Matthieu Carton, Nicolas Girard

Poster

Analysis of the Impact of Age and Brain Metastases in First Line Non-small Cell Lung Cancer Based in the Real-world Data of REVEAL Study

Juan Coves, Francisco de A. Aparisi, Bartomeu Massuti, Ana Cardeña-Gutiérrez, Juan Verdún, Victoria E. Castellón, Javier Garde-Noguera, Luis Cabezón-Gutiérrez, Ana Cobo Rodríguez, Sergio Vázquez, Esperanza Arriola, Alejandro Navarro, Manuel Cobo, Soledad Medina, Carmen Areses, Ana Laura Ortega Granados, Néstor Álvarez, David Vilanova, Carlos Aguado

Poster

Real-world Treatment and Response Patterns in Patients With Metastatic Non-small Cell Lung Cancer In Spain: REVEAL Study

Carlos Aguado de la Rosa, Francisco Aparisi Aparisi, Bartomeu Massuti Sureda, Ana Cardeña, Juan A. Verdún Aguilar, Victoria Castellón, Javier Garde-Noguera, Ana Cobo Rodríguez, Luis Cabezón-Gutiérrez, Sergio Vázquez Estevez, Esperanza Arriola Arellano, Alejandro Navarro Mendivil, Soledad Medina Valdivieso, Manuel Cobo Dols, M-Carmen Areses Manrique, Ana Laura Ortega Granados, Néstor Álvarez, David Vilanova Larena, Juan Coves Sartro

Oral

Phase II Study of Iza-bren (BL-B01D1) In Combination With Serplulimab In Patients with Small Cell Lung Cancer (SCLC)

Fei Zhou, Yongli Gao, Jin Zhou, Longhua Sun, Yan Yu, Dingzhi Huang, Tongmei Zhang, Conghua Xie, Qiming Wang, Jie Chen, Haiyong Wang, Liang Han, Zhen Wang, Zhiye Zhang, Bin Yang, Sa Xiao, Hai Zhu, Yi Zhu, Caicun Zhou

Poster

First-Line Pumitamig (PD-L1 × VEGF-A bsAb) Monotherapy in PD-L1+ Non-Squamous and Squamous Non-Small Cell Lung Cancer: Data from a Phase 1b/2a Trial in China

Liang Zhang, Dongqing Lv, Xingya Li, Jian Zhang, Huaxin Duan, Baogang Liu, Hui Zhao, Lijie He, Jiuwei Cui, Yueyin Pan, Tao Wu, Jia Zhao, Mei Ji, Suxia Luo, Lin Shen, Liqi Chen, Ruixia Chang, Ulug Gunaydin, Haifeng Liu

Poster

Progression-Free Survival and Overall Survival With Pumitamig (PD-L1 × VEGF-A bsAb) Plus Chemotherapy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Following Progression With EGFR TKI in China: Phase 2 Study Results

Yi-Long Wu, Zhen Wang, Haifeng Liu, Jian Fang, Xiangjiao Meng, Yueyin Pan, Hui Zhao, Yanqiu Zhao, Haichuan Su, Meili Sun, Tong Zhou, Ping Duan, Dongqing Lv, Yan Wang, Jingying Du, Wei Zuo, Chengjie Hu, Susu He, Peng Zhang, Tao Zhang

Poster

Phase 2 Study of First-Line Pumitamig (PD-L1 × VEGF-A bsAb) Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): Updated Efficacy and Safety Results

Ying Liu, Jianhua Shi, Xiangjiao Meng, Longhua Sun, Xingya Li, Dongqing Lv, Yueyin Pan, Jian Fang, Jun Chen, Xiuheng Qi, Baogang Liu, Susu He, Peng Zhang, Liqi Chen, Isaac Dai, Haifeng Liu

Poster

ROSETTA Lung-01 TiP: A Phase 3, Two-Stage Trial of Pumitamig, a PD-L1 × VEGF-A Bispecific Antibody, Plus Chemotherapy Versus Atezolizumab + Chemotherapy as First-Line Treatment in Patients With Extensive-Stage Small Cell Lung Cancer

Martin Reck, Ozgur Ozyilkan, Kailash Mosalpuria, Ahmet Sezer, Mehmet Ali Nahit Sendur, Kevin Franks, Carl Michael Gay, Vinod Ganju, Ina Nordman, Qing Zhou, Nicolas Girard, Ilhan Celik, Isaac Dai, Secil Koseoglu, Sarita Koride, Qiong Wang, Aurora O’Brate, Özlem Türeci, Ugur Sahin, John Heymach

Poster

ROSETTA Lung-02: A Global Phase 2/3, Randomized, Open-Label Trial of Pumitamig, a PD-L1 × VEGF-A Bispecific Antibody, in Combination With Chemotherapy in Patients (pts) With First-Line Non-Small Cell Lung Cancer

Solange Peters, Younjoo Lee, Mustafa Erman, Stephen V. Liu, Ben Solomon, Terufumi Kato, Shun Lu, Sanjay Popat, Ilhan Celik, Ulug Mutlu Gunaydin, René Bartz, Vikesh Patel, Shraddha Patel, Kevin Tsai, Li Li, Claudia-Nanette Gann, Aurora O’Brate, Ugur Sahin, Özlem Türeci, Byoung Chul Cho